Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Am J Transplant
; 19(11): 3018-3034, 2019 11.
Article
en En
| MEDLINE
| ID: mdl-31152476
Palabras clave
clinical research/practice; immunosuppressant - mechanistic target of rapamycin (mTOR); immunosuppressant - mechanistic target of rapamycin: everolimus; immunosuppression/immune modulation; immunosuppressive regimens - minimization/withdrawal; kidney transplantation/nephrology; liver transplantation/hepatology
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Complicaciones Posoperatorias
/
Trasplante de Riñón
/
Inhibidores de la Calcineurina
/
Everolimus
/
Rechazo de Injerto
/
Supervivencia de Injerto
/
Fallo Renal Crónico
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Transplant
Asunto de la revista:
TRANSPLANTE
Año:
2019
Tipo del documento:
Article
País de afiliación:
Países Bajos